To gain a more comprehensive understanding of the therapeutic potential of AT1R blockers on diabetic GI changes, we plan to extend our investigations to long-term diabetes models and evaluate the effects of ARBs after the onset of diabetes, in order to assess their curative potential. The gene discussed is AGTR1; the disease is diabetes mellitus.